167 related articles for article (PubMed ID: 37664851)
1. Obtaining SF-6D utilities from FACT-H&N in thyroid carcinoma patients: development and results from a mapping study.
Yang Q; Huang D; Jiang L; Tang Y; Zeng D
Front Endocrinol (Lausanne); 2023; 14():1160882. PubMed ID: 37664851
[TBL] [Abstract][Full Text] [Related]
2. Prediction of the SF-6D utility score from Lung cancer FACT-L: a mapping study in China.
Yang Q; Jiang LL; Li YF; Huang D
Health Qual Life Outcomes; 2023 Nov; 21(1):122. PubMed ID: 37964348
[TBL] [Abstract][Full Text] [Related]
3. Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma.
Huang D; Zeng D; Tang Y; Jiang L; Yang Q
Qual Life Res; 2024 Feb; 33(2):491-505. PubMed ID: 37938402
[TBL] [Abstract][Full Text] [Related]
4. Mapping study of papillary thyroid carcinoma in China: Predicting EQ-5D-5L utility values from FACT-H&N.
Huang D; Peng J; Chen N; Yang Q; Jiang L
Front Public Health; 2023; 11():1076879. PubMed ID: 36908441
[TBL] [Abstract][Full Text] [Related]
5. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
Yang Q; Yu XX; Zhang W; Li H
Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
[TBL] [Abstract][Full Text] [Related]
6. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
Hawton A; Green C; Telford C; Zajicek J; Wright D
Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
[TBL] [Abstract][Full Text] [Related]
7. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.
Teckle P; McTaggart-Cowan H; Van der Hoek K; Chia S; Melosky B; Gelmon K; Peacock S
Health Qual Life Outcomes; 2013 Dec; 11():203. PubMed ID: 24289488
[TBL] [Abstract][Full Text] [Related]
8. Mapping the Memorial Anxiety Scale for Prostate Cancer to the SF-6D.
Erim DO; Bennett AV; Gaynes BN; Basak RS; Usinger D; Chen RC
Qual Life Res; 2021 Oct; 30(10):2919-2928. PubMed ID: 33993437
[TBL] [Abstract][Full Text] [Related]
9. Mapping the Functional Assessment of Cancer Therapy-general or -Colorectal to SF-6D in Chinese patients with colorectal neoplasm.
Wong CK; Lam CL; Rowen D; McGhee SM; Ma KP; Law WL; Poon JT; Chan P; Kwong DL; Tsang J
Value Health; 2012 May; 15(3):495-503. PubMed ID: 22583460
[TBL] [Abstract][Full Text] [Related]
10. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
Yousefi M; Nahvijou A; Sari AA; Ameri H
Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
[TBL] [Abstract][Full Text] [Related]
11. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
Lamu AN; Olsen JA
Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
[TBL] [Abstract][Full Text] [Related]
12. Mapping the PHQ-8 to EQ-5D, HUI3 and SF6D in patients with depression.
Abdin E; Chong SA; Seow E; Tan KB; Subramaniam M
BMC Psychiatry; 2021 Sep; 21(1):451. PubMed ID: 34517871
[TBL] [Abstract][Full Text] [Related]
13. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
Liu T; Li S; Wang M; Sun Q; Chen G
Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
[TBL] [Abstract][Full Text] [Related]
14. Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis.
Kalaitzakis E; Benito de Valle M; Rahman M; Lindkvist B; Björnsson E; Chapman R; Kontodimopoulos N
Qual Life Res; 2016 Apr; 25(4):947-57. PubMed ID: 26471264
[TBL] [Abstract][Full Text] [Related]
15. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
16. Mapping the cancer-specific FACT-B onto the generic SF-6Dv2.
Nahvijou A; Safari H; Yousefi M; Rajabi M; Arab-Zozani M; Ameri H
Breast Cancer; 2021 Jan; 28(1):130-136. PubMed ID: 32712768
[TBL] [Abstract][Full Text] [Related]
17. Mapping the Positive and Negative Syndrome Scale scores to EQ-5D-5L and SF-6D utility scores in patients with schizophrenia.
Abdin E; Chong SA; Seow E; Verma S; Tan KB; Subramaniam M
Qual Life Res; 2019 Jan; 28(1):177-186. PubMed ID: 30382480
[TBL] [Abstract][Full Text] [Related]
18. Mapping between the Roland Morris Questionnaire and generic preference-based measures.
Khan KA; Madan J; Petrou S; Lamb SE
Value Health; 2014 Sep; 17(6):686-95. PubMed ID: 25236992
[TBL] [Abstract][Full Text] [Related]
19. Mapping the neck disability index to SF-6D in patients with chronic neck pain.
Zheng Y; Tang K; Ye L; Ai Z; Wu B
Health Qual Life Outcomes; 2016 Feb; 14():21. PubMed ID: 26879341
[TBL] [Abstract][Full Text] [Related]
20. The development of a model for translation of the Neck Disability Index to utility scores for cost-utility analysis in cervical disorders.
Richardson SS; Berven S
Spine J; 2012 Jan; 12(1):55-62. PubMed ID: 22209244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
